|
|
Itäinen Pitkäkatu 4 B
Turku, 20520 Finland
phone:
+358 2 4788 640
fax:
+358 2 4788 120 |
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
www.delsitech.com |
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Silica-based drug delivery technologies. |
 |
| Management |
| Harry Jalonen, PhD, MBA, Member of the Board, CEO; Kai Lähdesmäki, MSc, Chairman of the Board, Vice President; Jouni Heikkilä, MD, PhD, Specialist in orthopaedics and traumatology; Antti Yli-Urpo, DDS, PhD, Member of the Board, Professor University of Turku; Gunnar Björkstén, MBA, Vice President Business Development; Matti Peltola, MD, PhD, DDS, Member of the Board; Martti Hintikka, MSc(Eng), Member of the Board, Managing Director |
|
|
|
|
| Keywords |
| drugs, delivery, injectable, implant, small molecule, proteins, polysaccharides, viruses |
|
|
|
|
Description |
| DelSiTech specialises in a implant, subcutaneous and intra-muscular injectable technology for controlled release of small molecular drugs and biopharmaceuticals including proteins, polysaccharides and viruses. |
 |
| Products / Services |
The company operates in the development and licensing of long-term controlled drug delivery implant, subcutaneous or intramuscular formulations.
|
 |
| Technology / Differentiation |
| The DelSiTech technology, based on silica (SiO2) matrix, is flexible and applicable for synthetic small molecules but especially for labile biopharmaceuticals and for the preservation and controlled delivery of viruses. |
 |
 |
|
|
|
|